7JZM

SARS-CoV-2 spike in complex with LCB3 (local refinement of the RBD and LCB3)

7JZM の概要

• エントリーDOI: 10.2210/pdb7jzm/pdb
• EMDBエントリー: 22533
• 分子名称: LCB3, Spike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
• 機能のキーワード: sars-cov-2, covid-19, spike glycoprotein, fusion protein, neutralizing antibodies, structural genomics, seattle structural genomics center for infectious disease, ssgcid, inhibitor, viral protein
• 由来する生物種: synthetic construct; 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 154943.26

構造登録者

Park, Y.J.,Veesler, D.,Seattle Structural Genomics Center for Infectious Disease (SSGCID) (登録日: 2020-09-02, 公開日: 2020-09-23, 最終更新日: 2020-11-04)

• 主引用文献: Cao, L.,Goreshnik, I.,Coventry, B.,Case, J.B.,Miller, L.,Kozodoy, L.,Chen, R.E.,Carter, L.,Walls, A.C.,Park, Y.J.,Strauch, E.M.,Stewart, L.,Diamond, M.S.,Veesler, D.,Baker, D.; De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.; Science, 370:426-431, 2020; PubMed: 32907861; DOI: 10.1126/science.abd9909

実験手法

ELECTRON MICROSCOPY (3.5 Å)